Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.73 |
| ▸ | SCN4A | P35499 | 1/20 | 0.73 |
| ▸ | MC3R | P41968 | 1/20 | 0.73 |
| ▸ | HTR3A | P46098 | 1/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.73 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lidofenin SCHEMBL28279278 | 0.98 | MAPT (0.71) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidofenin SCHEMBL29765217 | 0.98 | MAPT (0.71) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Edetic Acid SCHEMBL17899413 | 0.88 | MAPT (0.81) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL28313393 | 0.87 | MAPT (0.97) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL28651403 | 0.86 | MAPT (0.88) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL27245471 | 0.86 | MAPT (0.88) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL22188608 | 0.85 | MAPT (0.94) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL8183082 | 0.85 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL5334354 | 0.85 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 | |
| Lidocaine SCHEMBL15689 | 0.85 | MAPT (1.00) | MAPTLMNASCN3AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-3977137-B1 | DETECTION OF ANALYTES BY NANOPORE WITHOUT USING ELECTRODES | NANJING UNIVERSITY (CN) | 2026-04-01 | — | — | EP | claimed |
| US-20260071943-A1 | METHOD FOR RECOVERING EXTRACELLULAR VESICLES | H.U. GROUP RESEARCH INSTITUTE G.K. (JP) | 2026-03-12 | — | — | US | claimed |
| US-12571110-B2 | Metal sulfide scale dissolver for oilfield application | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4696334-A2 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-12552981-B2 | Filter cake removal treatment fluid with chelating agent and viscoelastic surfactant | SAUDI ARABIAN OIL COMPANY (SA) | 2026-02-17 | — | — | US | claimed |
| US-20250376614-A1 | FILTER CAKE REMOVAL TREATMENT FLUID WITH CHELATING AGENT AND VISCOELASTIC SURFACTANT | SAUDI ARABIAN OIL CO (SA) | 2025-12-11 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0999855-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0166746-B1 | PREPARATION OF ?99M TC RADIOPHARMACEUTICALS | THE COMMONWEALTH OF AUSTRALIA (AU) | 1991-04-24 | — | — | EP | claimed |
| EP-0165728-B1 | NMR CONTRAST AGENTS | NYCOMED AS (NO) | 1988-12-14 | — | — | EP | claimed |
| US-4714607-A | NUCLEAR MAGNETIC RESONANCE | NYCOMED AS (NO) | 1987-12-22 | — | — | US | claimed |
| US-4272503-A | FORMING A STABLE COMPLEX OF LIGAND AND TECHNETIUM BY THE REDUCTION OF PERTECHNETATE BY A SUBSTRATE-CHELATE-REDUCING AGENT COMPLEX; LABELS; RADIOLOGY | NEW ENGLAND NUCLEAR CORPORATION (US) | 1981-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552981-B2 | Filter cake removal treatment fluid with chelating agent and viscoelastic surfactant | DKK1, PROC, SHH | MAPT 3494/4885LMNA 2613/4885SCN3A 2576/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | MAPT 3275/4885LMNA 1568/4885SCN3A 2840/4885 |
| US-20260071943-A1 | METHOD FOR RECOVERING EXTRACELLULAR VESICLES | EXOSC5, EXOSC9, EXOSC10 | MAPT 2626/4885LMNA 2620/4885SCN3A 2338/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | MAPT 3628/4885LMNA 1721/4885SCN3A 552/4885 |
| US-12571110-B2 | Metal sulfide scale dissolver for oilfield application | HKDC1, SLC7A11, DDHD2 | MAPT 2615/4885LMNA 2373/4885SCN3A 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.